Nigakinone enhances FXR expression to synergize with irinotecan in suppressing colorectal cancer cells and xenografts
Biochemical Pharmacology · 2026-07 · 249 · 117904
DOI: 10.1016/j.bcp.2026.117904 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Pharmacology, 2026-07. Verfasst von Yuanyuan Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Nanjing Drum Tower Hospital, China Pharmaceutical University, Nanjing 210008, China; School of Pharmacy, China Pharmaceutical University, Nanjing 210…. Hauptthemen laut MEDLINE: Irinotecan, Receptors, Cytoplasmic and Nuclear, Colorectal Neoplasms. Die Arbeit nennt 43 Literaturangaben. Gefördert von: Natural Science Foundation of Jiangsu Province, Fundamental Research Funds for the Central Universities, Medical Science and Technology Development Foundation, Nanjing Municipality Health Bureau.
Abstract (Originalsprache)
The use of irinotecan (CPT-11), a first-line chemotherapeutic agent for colorectal cancer (CRC), is limited by acquired drug resistance and severe adverse effects. It has been found that activation of farnesoid X receptor (FXR) signaling reduced the growth of CRC. Here, we investigated the combination of obeticholic acid (OCA), a well-characterized FXR agonist, with CPT-11 as a potential therapeutic combination for CRC. In vitro experiments demonstrated that the OCA-CPT-11 synergistically inhibited proliferation and migration in FXR-high HT29 and SW620 cells, but exhibited minimal synergy in FXR-low HCT116 and Caco-2 cells. Genetic knockdown of FXR in HT29 cells attenuated the synergistic effects, whereas FXR overexpression in HCT116 cells enhanced them. These findings indicate that the synergistic effect of OCA-CPT-11 depends on basal FXR expression levels, highlighting the need to identify both FXR inducers and agonists. Through literature and database screening, silibinin (SB) and nigakinone (Nig) were identified to upregulate and activate FXR. Both SB-CPT-11 and Nig-CPT-11 exhibited strong synergistic anti-CRC effects in vitro, even under low FXR conditions. Nig achieved synergy with CPT‑11 at lower effective concentrations than SB, so it was prioritized as the lead candidate for in vivo evaluation. Consistently, the Nig-CPT‑11 combination synergistically inhibited the growth of HCT116 subcutaneous xenograft tumors in vivo. Notably. In summary, combining FXR inducers and agonists with CPT-11 offers a promising strategy for the treatment of CRC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nanjing Drum Tower Hospital, China Pharmaceutical University, Nanjing 210008, China; School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
- School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
- Affiliated Jiangning Hospital of Chinese Medicine, China Pharmaceutical University, Nanjing 211100, China.
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
- Nanjing Drum Tower Hospital, China Pharmaceutical University, Nanjing 210008, China. Electronic address: juliandth@163.com.
- School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China; Affiliated Jiangning Hospital of Chinese Medicine, China Pharmaceutical University, Nanjing 211100, China. Electronic address: peizhang@cpu.edu…
Förderung
- Natural Science Foundation of Jiangsu Province
- Fundamental Research Funds for the Central Universities
- Medical Science and Technology Development Foundation, Nanjing Municipality Health Bureau
- National Natural Science Foundation of China
- China Pharmaceutical University
Zitieren
APA
Zhang, Y., Liu, M., Zhang, Y., Qin, F., Tian, Y., Xu, F., Zhang, Y., & Zhang, P. (2026). Nigakinone enhances FXR expression to synergize with irinotecan in suppressing colorectal cancer cells and xenografts. Biochemical Pharmacology, 249, 117904. https://doi.org/10.1016/j.bcp.2026.117904
Vancouver
Zhang Y, Liu M, Zhang Y, Qin F, Tian Y, Xu F, et al. Nigakinone enhances FXR expression to synergize with irinotecan in suppressing colorectal cancer cells and xenografts. Biochemical Pharmacology. 2026;249:117904. doi:10.1016/j.bcp.2026.117904
BibTeX
@article{Zhang2026,
author = {Zhang, Yuanyuan and Liu, Mingyang and Zhang, Yifan and Qin, Fengxia and Tian, Yuan and Xu, Fengguo and Zhang, Yuxin and Zhang, Pei},
title = {Nigakinone enhances FXR expression to synergize with irinotecan in suppressing colorectal cancer cells and xenografts},
journal = {Biochemical Pharmacology},
year = {2026},
volume = {249},
pages = {117904},
doi = {10.1016/j.bcp.2026.117904}
}
EUVIMED